8-K: Aimei Health Extends Business Combination Deadline

Aimei Health Technology Co., Ltd. extends its deadline to complete a business combination to February 6, 2026, funded by a $34,330.96 promissory note.

Summary

• The company extended its period to consummate its initial business combination by one month, from January 6, 2026, to February 6, 2026.
• This marks the fourteenth extension permitted under the company's Amended and Restated Articles of Association.
• An Extension Payment of $34,330.96 was deposited into the trust account for public shareholders.
• To fund the Extension Payment, the company issued an unsecured promissory note in the total principal amount of $34,330.96 to Aimei Health Ltd (the Sponsor) and United Hydrogen Group Inc. (the Payees).
• Each Payee contributed $17,165.48 to the Extension Payment.
• The Promissory Note does not bear interest and its principal becomes due and payable upon the consummation of a business combination with United Hydrogen.
• The Payees have the right, but not the obligation, to convert the Promissory Note, in whole or in part, into private units of the company at a price of $10.00 per unit, immediately prior to the business combination.

Sentiment

Score: 4

Explanation: The extension provides more time, which is positive for the continuation of the business combination process. However, it is the fourteenth extension, indicating significant ongoing challenges and prolonged uncertainty. The new debt and potential dilution are also negative factors.

Positives

• Secured an additional month to complete the business combination, extending the deadline to February 6, 2026.
• The Extension Payment of $34,330.96 was deposited into the trust account for public shareholders.
• The promissory note issued to fund the extension does not bear interest, reducing immediate financial burden.

Negatives

• The company required a fourteenth extension, indicating prolonged difficulty in completing its initial business combination.
• Incurred a new financial obligation of $34,330.96 through an unsecured promissory note.
• Potential for dilution if the promissory note is converted into private units by the Payees.

Risks

• Failure to consummate the business combination with United Hydrogen Group Inc. by the new termination date of February 6, 2026.
• Potential dilution for existing shareholders if the promissory note is converted into private units at $10.00 per unit.
• Reliance on the Sponsor and United Hydrogen Group Inc. for funding extensions.
• The promissory note has not been registered under the Securities Act of 1933, which limits its transferability.

Future Outlook

The company aims to consummate its initial business combination with United Hydrogen Group Inc. by the newly extended termination date of February 6, 2026.

Management Comments

• Junheng Xie, Chief Executive Officer and Director, signed the report on behalf of Aimei Health Technology Co., Ltd.

Industry Context

This filing is typical for a Special Purpose Acquisition Company (SPAC) that is nearing its initial business combination deadline and requires additional time to finalize a deal. Multiple extensions are not uncommon in the SPAC market, especially in challenging economic environments or for complex transactions, reflecting the difficulties many SPACs face in completing their mergers.

Comparison to Industry Standards

• Many SPACs, such as those observed in the 2022-2024 period, have faced challenges in identifying and completing suitable business combinations within their initial timeframe, leading to multiple extensions.
• Sponsor-funded extensions via promissory notes, often with conversion rights into private units, are a common mechanism for SPACs to gain more time, similar to extensions seen with companies like Digital World Acquisition Corp. or Gores Holdings.
• The $10.00 per unit conversion price for private units is a standard valuation point for SPACs, aligning with the typical IPO price of SPAC units.

Corporate Governance

Related Party Transactions

• An unsecured promissory note of $34,330.96 was issued to Aimei Health Ltd (the Sponsor) and United Hydrogen Group Inc. (the target company for the business combination) to fund the extension payment.

Stakeholder Impact

• Shareholders face continued uncertainty regarding the business combination and potential dilution if the promissory note is converted into private units.
• Creditors (Aimei Health Ltd and United Hydrogen Group Inc.) now hold an unsecured promissory note, representing a claim against the company, though it is interest-free.

Next Steps

• Consummate the initial business combination with United Hydrogen Group Inc. by February 6, 2026.

Key Dates

Recommendation

The filing indicates continued efforts to complete a business combination, which is a positive for a SPAC. However, the need for a fourteenth extension and the associated debt, even if interest-free, signal persistent challenges and prolonged uncertainty. Investors should hold, awaiting definitive news on the business combination, as the current situation presents both the potential for a deal and the risk of further delays or termination.

Keywords

Aimei Health Technology, SPAC, business combination, extension, promissory note, United Hydrogen Group, Nasdaq, AFJK, trust account, corporate governance